StockData
Revolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD) stock

RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 3/30
$191.31+1.04 (+0.55%)

Close on Oct 30, 2026Market cap $41.00BP/E –Yield –

Earnings

Revolution Medicines's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$3.06
Latest guidance
Raised
Aug 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Revolution Medicines's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close––-$3.06Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 7, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close––-$1.12Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close––-$0.94Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close––-$0.81Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close––-$0.70Release
Q4 FY2023ended Dec 31, 2023Feb 26, 2024after the close$700.00K-95.4%-$1.14Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Revolution Medicines's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
estimated non-cash stock-based compensation expenseFY2026$270.00M – $290.00M–RaisedAug 5, 2026
GAAP operating expenseGAAPFY2026$2.10B – $2.20B–RaisedAug 5, 2026
GAAP operating expensesGAAPFY2026$1.70B – $1.80B$1.60B – $1.70BRaisedMay 6, 2026
non-cash stock-based compensation expenseFY2026$180.00M – $200.00M–NewFeb 25, 2026
stock-based compensation expenseFY2026$260.00M – $280.00M–RaisedMay 6, 2026

Guidance history

Every forecast Revolution Medicines put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026GAAP operating expenseFY2026$2.10B – $2.20BRaised
Aug 5, 2026estimated non-cash stock-based compensation expenseFY2026$270.00M – $290.00MRaised
May 6, 2026GAAP operating expensesFY2026$1.70B – $1.80BRaised
May 6, 2026stock-based compensation expenseFY2026$260.00M – $280.00MRaised
Feb 25, 2026GAAP operating expensesFY2026$1.60B – $1.70BNew
Feb 25, 2026non-cash stock-based compensation expenseFY2026$180.00M – $200.00MNew
Nov 5, 2025GAAP net lossFY2025$1.03B – $1.09BRaised
Nov 5, 2025estimated non-cash stock-based compensation expenseFY2025$115.00M – $130.00MNew
Aug 6, 2025GAAP net lossFY2025-$1.09B – -$1.03BNew
May 7, 2025GAAP net lossFY2025$840.00M – $900.00MReaffirmed
May 7, 2025estimated non-cash stock-based compensation expenseFY2025$115.00M – $130.00MNew
Feb 26, 2025GAAP net lossFY2025$840.00M – $900.00MNew
Nov 6, 2024GAAP net lossFY2024-$600.00M – -$560.00MLowered
Nov 6, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed
Aug 7, 2024GAAP net lossFY2024$560.00M – $600.00MRaised
Aug 7, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed
May 8, 2024GAAP net lossFY2024$480.00M – $520.00MReaffirmed
May 8, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MReaffirmed
Feb 26, 2024GAAP net lossFY2024$480.00M – $520.00MNew
Feb 26, 2024estimated non-cash stock-based compensation expenseFY2024$70.00M – $80.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Revolution Medicines filed with the SEC as exhibits to Form 8-K or 6-K

  1. Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
    Results
  2. Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
    Results
  3. Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
    Results
  4. Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
    Results
  5. Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
    Results
  6. Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development
    Update
  7. Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
    Results
  8. Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
    Results
  9. Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
    Results
  10. Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
    Results
  11. Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
    Results
  12. Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
    Results
  13. Quarterly results release
    Results
  14. Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
    Results
  15. Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend
    Update